{"version":"1.0","type":"link","title":"Lenvatinib combined with immune checkpoint inhibitors for unresectable, recurrent, or metastatic hepatocellular carcinoma: a real-world study.","author_name":"Kong H 외","author_url":"https://prs-insight.online/author/Kong%20H","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/106342","thumbnail_width":1200,"thumbnail_height":630}